Reports related to this article:
Plant(s): View 21 related plants in PECWeb
Released December 03, 2014 | SUGAR LAND
en
Reported by Annette Kreuger for Industrial Info Resources (Sugar Land, Texas)--Pharmaceutical company Allergan (NYSE:AGN) (Irvine, California) has accepted a $66 billion buyout offer from Actavis (NYSE:ACT) (Dublin, Ireland), following months of pursuit by Valeant Pharmaceuticals (NYSE:VRX) (Laval, Quebec). Allergan, known chiefly for wrinkle reducer Botox, had continually spurned Valeant's offers, which had reached a peak of $53 billion last May.
See below for a list of Actavis and Allergan manufacturing plants & research sites in North America.
Actavis will spend $219 in cash and stock for each share of Allergan, considerably higher than the $179 for the same that Valeant offered. In addition to the popular Botox, Actavis is eager to add Allergan's promising experimental eye treatments for macular degeneration and glaucoma into its pipeline.
The Actavis deal was unanimously approved by Allergan's board, with Allergan Chairman and CEO David E.I. Pyott commenting: "We are combining with a partner that is ideally suited to realize the full potential inherent in our franchise."
The Allergan deal follows a spurt of recent Actavis buys. Earlier this year, the company scooped up Forest Laboratories for $28 billion, after acquiring Irish drugmaker Warner-Chilcott for $8.5 billion in 2013. The Warner-Chilcott purchase spurred a move of Actavis' headquarters from Parsippany, New Jersey, to Dublin, Ireland, in part to take advantage of enormous tax savings.
Once the deal makes it through the approval process, and the buy is complete, Actavis expects to make the list of the top 10 global pharmaceutical companies by sales revenue, with combined annual pro-forma revenues of more than $23 billion anticipated in 2015.
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, three offices in North America and 10 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities.
See below for a list of Actavis and Allergan manufacturing plants & research sites in North America.
Actavis will spend $219 in cash and stock for each share of Allergan, considerably higher than the $179 for the same that Valeant offered. In addition to the popular Botox, Actavis is eager to add Allergan's promising experimental eye treatments for macular degeneration and glaucoma into its pipeline.
The Actavis deal was unanimously approved by Allergan's board, with Allergan Chairman and CEO David E.I. Pyott commenting: "We are combining with a partner that is ideally suited to realize the full potential inherent in our franchise."
The Allergan deal follows a spurt of recent Actavis buys. Earlier this year, the company scooped up Forest Laboratories for $28 billion, after acquiring Irish drugmaker Warner-Chilcott for $8.5 billion in 2013. The Warner-Chilcott purchase spurred a move of Actavis' headquarters from Parsippany, New Jersey, to Dublin, Ireland, in part to take advantage of enormous tax savings.
Once the deal makes it through the approval process, and the buy is complete, Actavis expects to make the list of the top 10 global pharmaceutical companies by sales revenue, with combined annual pro-forma revenues of more than $23 billion anticipated in 2015.
| Actavis/Allergan Manufacturing Plants & Research Sites in North America | ||
|---|---|---|
| Plant ID | Plant Name | State |
| 3049856 | North Brunswick Global R&D Technology Center | New Jersey |
| 1519143 | Vandalia Orally Disintegrating Tablets, Capsules & Sachets | Ohio |
| 3108015 | Fall River Levadex Inhalables | Massachusetts |
| 1061591 | Weston Generic Pharmaceutical Distribution | Florida |
| 1063064 | Mont Saint Hilaire Ointments, Oral Liquids & Solid Doses | Quebec |
| 1518311 | Santa Barbara Surgical Implant Device R&D | California |
| 1062256 | Corona Generic Solid Dose Tablets & Capsules | California |
| 1062726 | Salt Lake City Transdermals, Gels & Ointments OTC's | Utah |
| 1080083 | Campbell Botox Cosmetic Injectables | California |
| 1063249 | Commack Lexapro & Other Tablets/Teflaro Injectable | New York |
| 3034456 | Olive Branch Generic Pharma Distribution | Mississippi |
| 1513200 | Copiague Generic Nicotine Gums | New York |
| 1012747 | Irvine Sterile Injectables, Eye Drops & Cream Mid Stage R&D | California |
| 1510460 | Elizabeth Generic Oral Solid Doses, Tablets, Capsules | New Jersey |
| 1030110 | Manati Pharmaceutical Warehouse and Distribution | Puerto Rico |
| 1061463 | Fajardo Female Health Prods, Dermatology, Urology | Puerto Rico |
| 1063220 | Cincinnati Tablets, Capsules & Other Solid Doses and Liquids | Ohio |
| 1063238 | Farmingdale Pharmaceuticals R&D | New York |
| 1001565 | Waco Injectable Gels, Medical Devices and Eye Drops | Texas |
| 3040335 | Bridgewater Biologics Botox R&D | New Jersey |
| 1058672 | Davie Generic Solid Dose Tablets & Capsules | Florida |
| 3081567 | Blue Ash Branded Pharmaceutical Packaging and Testing* | Ohio |
| *under construction |
